These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2380920)

  • 21. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On a reasonable disaggregate criterion of population bioequivalence admitting of resampling-free testing procedures.
    Wellek S
    Stat Med; 2000 Oct; 19(20):2755-67. PubMed ID: 11033573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance intervals for assessing individual bioequivalence.
    Brown EB; Iyer HK; Wang CM
    Stat Med; 1997 Apr; 16(7):803-20. PubMed ID: 9131767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size considerations for establishing clinical bioequivalence of allergen formulations.
    Rabin RL; Slater JE; Lachenbruch P; Pastor RW
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):24-33. PubMed ID: 15119019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence of generic thioridazine drug products--the FDA viewpoint.
    Hamrell MR; Martinez MN; Dighe SV; Parkman PD
    Drug Intell Clin Pharm; 1987 Apr; 21(4):362-72. PubMed ID: 3569040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.